Last update: May 1, 2016


Low Risk for breastfeeding

Moderately safe. Probably compatible.
Mild risk possible. Follow up recommended.
Read the Comment.

Synthetic drug and nucleoside analogue which is structurally related to guanine with antiviral activity.
It is used in infants and newborns for treatment of respiratory syncytial virus (RSV) and adenovirus. Along with interferon for treatment of hepatitis C (authorized on these cases from the 3 years of life).

At latest update no published data on excretion into breast milk were found.

Its large volume of distribution makes it unlikely that may occur the passage of significant amounts to the milk.
Its low oral bioavailability hinder the passage toward infant’s plasma from ingested milk, except in preterm milk and immediate neonatal period, for which there may be an increased intestinal permeability.

Since it is used as treatment on infants and its pharmacokinetic data are favorable, it should be regarded as compatible with breastfeeding for short-term exposures, however, to be cautiously used on long-term treatments.


Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Ribavirin is also known as

Ribavirin in other languages or writings:


Ribavirin belongs to this group or family:


Main tradenames from several countries containing Ribavirin in its composition:


Variable Value Unit
Oral Bioavail. 45 - 65 %
Molecular weight 244 daltons
Protein Binding 0 %
VD 69 l/Kg
Tmax 1,5 hours
T1/2 298 hours


  1. Ronchi A, Doern C, Brock E, Pugni L, Sánchez PJ. Neonatal adenoviral infection: a seventeen year experience and review of the literature. J Pediatr. 2014 Abstract
  2. Christensen VB, Nordly S, Fischler B, Kjær MS, Jørgensen MH. [Hepatitis C infection in children.] Ugeskr Laeger. 2014 Abstract
  3. Le Campion A, Larouche A, Fauteux-Daniel S, Soudeyns H. Pathogenesis of hepatitis C during pregnancy and childhood. Viruses. 2012 Abstract Full text (link to original source) Full text (in our servers)
  4. Durmaz O. Hepatitis C infection in childhood. Clin Res Hepatol Gastroenterol. 2012 Abstract
  5. Arshad M, El-Kamary SS, Jhaveri R. Hepatitis C virus infection during pregnancy and the newborn period--are they opportunities for treatment? J Viral Hepat. 2011 Abstract
  6. Ventre K, Randolph A. WITHDRAWN: Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children. Cochrane Database Syst Rev. 2010 Abstract
  7. Ksiezakowska K, Laszczyk M, Wilczyński J, Nowakowska D. [SARS-CoV infection and pregnancy]. Ginekol Pol. 2008 Abstract
  8. Fischler B. Hepatitis C virus infection. Semin Fetal Neonatal Med. 2007 Abstract
  9. Mahadevan U, Kane S. American gastroenterological association institute technical review on the use of gastrointestinal medications in pregnancy. Gastroenterology. 2006 Jul;131(1):283-311. Review. Abstract Full text (link to original source) Full text (in our servers)
  10. Davison C, Ventre KM, Luchetti M, Randolph AG. Efficacy of interventions for bronchiolitis in critically ill infants: a systematic review and meta-analysis. Pediatr Crit Care Med. 2004 Abstract Full text (link to original source) Full text (in our servers)

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write to us at

e-lactancia is a resource recommended by El Parto Es Nuestro from Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM